Clinical trial
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
NCT00411749 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00411749 |
|---|---|
| Title | V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) |
| Official title | V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HPV Infections |
| Intervention type | Biological |
| Interventions | Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501), Comparator: Placebo (unspecified) |
| Enrollment | 107 |
| Start date | Dec 11, 2006 |
| Primary completion | Sep 18, 2009 |
| Completion | Sep 18, 2009 |
| First posted | Dec 15, 2006 |
| Last update posted | Apr 21, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: